JP Morgan Initiates Coverage of XOMA

Analyst Franklin Berger says the company's Xanelim is a potential blockbuster drug

JP Morgan initiated investment coverage of XOMA Ltd. (XOMA ) with a buy rating and set a $17 price target on the stock.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.